Indicators

Markets:

News

Latest News about Joseph Tucker

Recent news which mentions Joseph Tucker

Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results

November 25, 2024

Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders

November 18, 2024

Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal

November 12, 2024

Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic

October 15, 2024

Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies

October 04, 2024

Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences' Breakthrough Research

September 25, 2024

Non-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally

July 25, 2024

New Patented Psychedelic Drug Brings Hope For Brain Disorder Therapies

July 11, 2024

'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand

May 16, 2024

Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate

May 14, 2024

Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods

May 08, 2024

Enveric Completes Manufacturing Of Its Psilocin Prodrug To Supply Drug Material For Completion Of Preclinical Program

August 21, 2023

Enveric Unveils Positive Results From Preclinical Studies Supporting Metabolic Profile Of Its Psilocin Prodrug For Anxiety

July 24, 2023

Enveric Unveils Positive Results From Animal Studies Of Its Psilocin Prodrug For Anxiety

July 17, 2023

Psychedelics Company Takes 'A Key Step' With New Formulation Of Its Psilocin Prodrug For Anxiety

June 26, 2023

Enveric Stock Trading Higher On Notice Of Allowance For Patent Application For Its Carboxylated Psilocybin Derivatives

June 05, 2023

Enveric Stock Soars On Reception Of Notice Of Allowance For Patent Application For Its Psilocin Prodrug Designs

May 24, 2023

Enveric Releases Paper Detailing The Development Of Novel Psilocin Prodrugs For The Treatment Of Mental Health Disorders

May 22, 2023

Enveric Biosciences Receives Notice Of Allowance From US Patent And Trademark Office For Novel Prodrug Of Psilocin

May 18, 2023

Enveric Biosciences Q1 Net Loss Of $4.80M, More On Basic And Diluted Loss Per Share

May 15, 2023

EXCLUSIVE: Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'

April 14, 2023

Enveric Biosciences Files Provisional Patent For CBD+Celecoxib Conjugate For Osteoarthritis

February 08, 2022

Cannabis Movers & Shakers: NORML, TGOD, Enveric Biosciences, Dalwhinnie Enterprises

December 10, 2021

Nasdaq Welcomes New Psychedelics Company In $23M M&A Transaction

September 17, 2021

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

© 2025 FinancialContent. All rights reserved.